WO2005094858A1 - 抗糖尿病用組成物 - Google Patents
抗糖尿病用組成物 Download PDFInfo
- Publication number
- WO2005094858A1 WO2005094858A1 PCT/JP2005/006319 JP2005006319W WO2005094858A1 WO 2005094858 A1 WO2005094858 A1 WO 2005094858A1 JP 2005006319 W JP2005006319 W JP 2005006319W WO 2005094858 A1 WO2005094858 A1 WO 2005094858A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- petals
- safflower
- extract
- water
- antidiabetic composition
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7032—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyldiacylglycerides, lactobionic acid, gangliosides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/286—Carthamus (distaff thistle)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Definitions
- the present invention relates to an antidiabetic composition, and more particularly, to an Asteraceae plant safflower (
- the present invention relates to a preventive and therapeutic agent for diabetes and a health food containing petals and Z or an extract thereof as an active ingredient.
- the present invention relates to a preventive and therapeutic agent for diabetes and a health food containing red pigment carthamin, yellow pigment safflower yellows, and saflorin A as active ingredients, which are contained in the petals of a banana flower.
- Examples of typical adult diseases include hypertension, diabetes, obesity, and hyperlipidemia (hypercholesterolemia). Diabetes is considered to be the cause of all chronic vascular diseases. Diabetes is one of the most common lifestyle-related diseases in Japan.
- diabetes A characteristic of diabetes is that when carbohydrate derived from dietary intake is absorbed into the blood by gastrointestinal absorption, blood sugar levels are too high or hyperglycemia persists. Diabetes often accompanies obesity and develops after a minor rise in blood sugar called the "pre-diabetes group.”
- Type II diabetes has been increasing in recent years.
- Type II diabetes often develops due to lack of exercise and irregular diet.
- Sulfo-pumurea-based preparations that promote insulin secretion, oc-dalcosidase inhibitors that suppress postprandial hyperglycemia, or thiazolidin-based preparations that recently improve insulin resistance are used for treatment.
- the preparation requires a prescription and is not easily available, and may have various side effects depending on the administration or administration of the preparation.
- a-Dalcosidase inhibitors and other antidiabetic drugs have recently been Severe liver damage is reported, and strict management and guidance from a physician is required for its use. Therefore, there is a need for one that is easily available and has as few side effects as possible.
- Examples of those that are easily available and have few side effects include so-called health foods in which a functional substance derived from a natural product is used as an active ingredient.
- a functional substance derived from a natural product is used as an active ingredient.
- an indigestible dextrin having an action of reducing the amount of sugar absorbed by the small intestine is blended as a natural substance-derived functional substance.
- Foods for food are "
- Foods containing such natural products are readily available when needed without the need for a prescription, so they can be taken in conjunction with a regular diet and are effective for early treatment of diabetes.
- Patent Literature 1 discloses an anti-diabetic agent derived from indigo belonging to the Polygonaceae plant
- Patent Literature 2 discloses an anti-diabetic agent derived from leguminous plant Funella 'Lingua
- Patent Literature 3 discloses a plant belonging to the genus Cubanoso genus Lily For preventing and treating diabetes.
- Many health foods claiming anti-diabetic effects are recognized, but there are many questions about their efficacy, and few of them have been specifically proven to be effective or effective in vivo.
- Patent Document 1 JP-A-2002-179587
- Patent Document 2 Japanese Patent Application Laid-Open No. 2002-332239
- Patent Document 3 JP 2003-81858 A
- An object of the present invention is to provide a side effect that can be easily obtained and ingested in a daily diet, thereby suppressing a postprandial hyperglycemic state and effectively preventing the onset of diabetes and alleviating symptoms.
- the present invention provides an antidiabetic agent containing an active ingredient derived from a natural plant with a low content of a plant.
- An object of the present invention is to provide a novel antidiabetic agent used as a component. Means for solving the problem
- the present inventors searched for various unknown plants, and performed various evaluations on them.
- the petals of the Asteraceae plant, safflower (Carthamus tinctorius), were examined.
- the red pigment carthamin and yellow pigment safflower yellows contained in Z or its extract, or banana petals were found to be effective as preventive and therapeutic agents for diabetes and health foods.
- the present invention relates to an antioxidant containing safflower A, a red pigment carthamine, a yellow pigment safflower yellow contained in petals and Z or an extract thereof, or a petal of asteraceous plant safflower (Carthamus tinctorius L.).
- the present invention relates to a composition for diabetes. The invention's effect
- the banana petals of the present invention and Z or an extract thereof have an effect of suppressing an increase in blood glucose during glucose load. Therefore, they can suppress the hyperglycemic state after eating or drinking due to overeating or unbalanced eating. It can also be used effectively as a therapeutic agent for diabetes, which can be said to be a representative of lifestyle-related diseases. In addition, since it is a natural drug derived from plants based on long-term experience, it can be used at low cost without worrying about side effects and is also effective in preventing diet and diabetes.
- the powder and Z or extract of the banana petal of the present invention can be taken as a health food in a chewy form, for example, a confectionery or a drink, and can be easily taken. It can be taken continuously for a long time.
- Bee-bana is a plant of the genus Bee-bana of the family Asteraceae for 1-2 years and its scientific name (
- Carthamus tinctorius indicates the meaning of both genus and species, and in Japan Since ancient times, it has been cultivated as a representative natural dye material along with eye and murasaki. Power that is widely cultivated in Japan especially in the Mogami River basin in Yamagata Prefecture Recently, safflower has been imported from China.
- the petal pigments of bananas include red safflower yellow, which is also used as an edible pigment, in addition to the red pigment carthamin, which is used as a cosmetic material such as lipstick and blusher. The range is diverse.
- Saffra yellows are a general term for yellowish banana pigments. Safflower yellows include safhu min A, safflower yellow B, saphromin C, and precursors.
- safflower has long been used as a medicinal herb, and its effects on irregular menstruation, chills, menopause, impaired blood circulation, etc. have attracted attention, and its pharmacological effects have been reviewed in recent years.
- JP-A-2001-346555 discloses an effect of effectively reducing active oxygen in an extract of cotyledons and stems of safflower.
- JP-A-2000-236838 discloses that red bean cedar is mainly used.
- the effect of obstetrics and gynecological diseases on foods in which safflower petal dry powder is added to the raw material is described in JP-A 2001-506589.
- a mixed composition containing 17 natural drugs such as cordyceps and safflower is used for treating diabetes. The effect is described in Japanese Patent Application Laid-Open No. 7-322825.
- Hei 2-207023 discloses a hot water of safflower as a healthy ice cream for preventing diabetes and the like, including those using a green sprouts portion of safflower sprouts. It has been reported as a poultice prepared by adding menthol to the extract.
- Japanese Patent Application Laid-Open No. 2003-40780 discloses an effect of suppressing the hypercholesterolemia by the red pigment carthamin of the petal of bana.
- the antidiabetic composition of the present invention comprises, as an active ingredient, asteraceous plant safflower (Carthamus
- the banana which can be used for the preventive and therapeutic agent for diabetes of the present invention can be either fresh flower or dried flower, such as domestic "Mogami safflower", Chinese, Israeli, American and Indian vegetation. Examples include bananas, but may be of any type without being limited to the locality of the production of bananas. In addition, a commercialized banana yellow pigment preparation or a red pigment preparation may be used. It is possible to stably provide a high blood sugar level-inhibiting agent irrespective of differences in petal lots, such as the type of safflower petals, the place of production, the timing of purchase, and the storage conditions.
- the active ingredient is generally prepared by the following method unless a commercially available commercialized banana yellow pigment preparation or red pigment preparation is used.
- raw or dried petals of safflower (Carthamus tinctorius L.), which is a raw material, are pulverized using common pulverization means.
- the pulverization should be performed to the extent that the effective component can be sufficiently eluted from the petals of safflower (for example, a size of about 5 mm or less), which need not be performed until the powder is finely ground.
- This pulverized product may be used as it is as an active ingredient of the antidiabetic composition, or petals that have been further pulverized into a powder form may be used as the active component.
- the pulverized product is added to a solvent and extracted at room temperature or by heating.
- the extraction solvent include alcohols having 1 to 8 carbon atoms, such as methanol and ethanol, water, a mixed solvent of water and the alcohols, ethyl acetate, and acetone.
- the extraction solvent is used in an amount of about 2 to about L00 by weight, preferably about 2 to 50 times by weight based on the petals of the banana.
- the extraction temperature and extraction time vary depending on the extraction solvent used.For example, when using aqueous methanol as the extraction solvent, it is recommended to heat and extract at a temperature of about 30 to 80 ° C for about 3 to 24 hours. Preferred,.
- the extraction solvent is evaporated under reduced pressure (for example, about 750 mmHg or less) to concentrate and solidify the residue, whereby an extract extract as an active ingredient can be obtained.
- the extract extracted with water or hot water is used after being lyophilized by freeze-drying.
- the extract or freeze-dried product thus prepared can exert a strong blood sugar level increase inhibitory effect when used as it is, but if necessary, can be further purified to reduce its activity and effect. It is possible to increase it further.
- a preparation obtained by freeze-drying the water-extracted extract from safflower petals obtained by the above procedure contains the yellow pigment safflower yellow, and this preparation exerts a stronger inhibitory effect on blood sugar rise. I can do it.
- the thus obtained yellow pigment saflower yellow can be used as a prophylactic and therapeutic agent for diabetes by exerting a strong blood sugar level inhibitory effect, such as a yellow pigment such as saflorin A, which is further purified by a known method. Can be used as health food.
- the remaining water-insoluble matter or the petals of the banana obtained by the water extraction of the petals of the banana are treated under basic conditions in an aqueous medium using wood ash, sodium bicarbonate solution, and the like, which have been conventionally used.
- the liquid layer portion excluding the insoluble matter is treated under acidic conditions in an aqueous medium using brewing vinegar, acetic acid, citric acid, etc., and the precipitate obtained contains the red pigment carthamin, It exerts a strong blood sugar rise inhibitory effect.
- the aqueous medium means water or a mixed solvent of water and an organic solvent soluble in water.
- the thus obtained sediment containing red pigment carthamin a highly pure red pigment cartamine which is further purified by a known method, exerts a strong blood sugar level inhibitory action to prevent and treat diabetes. It can be used as a healthy food.
- the purification method include a method using a chromatographic method, an elution method using an ion exchange resin, a recrystallization method, or the like, alone or in combination.
- chromatographic methods include normal phase chromatography, reverse phase chromatography, high performance liquid chromatography, centrifugal liquid chromatography, column chromatography, Examples thereof include a method using any one of thin-layer chromatography and the like or a combination thereof.
- Purification conditions such as a carrier and an elution solvent at this time can be appropriately selected according to various types of chromatography.
- a solvent of a form-mouth methanol system can be used
- reverse phase chromatography a water-methanol solvent can be used.
- the obtained extract is diluted and dissolved in water or lower alcohol, and the solution is contacted with an ion exchange resin to be adsorbed, and then the lower alcohol or water is added. Elution method.
- the lower alcohol used at this time is as described above, and among them, methanol is preferable.
- the ion exchange resin is not particularly limited as long as it is generally used in a purification treatment in the field.For example, a porous crosslinked polystyrene resin having a large network structure, Amberlite, Cellulose and the like can be mentioned. Polyamide column chromatography is also used as an effective elution method for aqueous solution components.
- the amount of powder and Z or extract of safflower petals used depends on the symptoms when used as a prophylactic and / or Z agent or therapeutic agent.
- 1-: LOOOmg, red pigments such as carthamin itself, safflower yellows themselves, and saphlomin A and other pigments l-1000mg are preferred. .
- composition for anti-diabetes of the present invention comprises, based on the total weight thereof, the petals of the Asteraceae plant, banana, the extract from the banana petal, or the red pigment carthamin itself obtained therefrom, or the yellow pigment saflorin A ⁇ saflower at least yellow compound itself, from 1 to 40 weight 0/0, preferably contains 2 to 20 wt%.
- banana petals and Z or an extract thereof can also be used for health foods.
- Health foods are foods that are more aggressive than normal foods and are intended to promote health, maintain and promote health, and include, for example, liquid or semi-solid and solid products, such as cookies, Examples include confectionery such as rice crackers, jelly, yokan, yogurt, and buns, soft drinks, nutritional drinks, and soups. Also, it may be decocted as it is to make a tea preparation. Mix or apply the above powder, extract, etc. in the manufacturing process of these foods or on the final product. It can be made into health food by adding it as fog.
- the health food of the present invention comprises, for example, 0.1 to 5 g of bee petals obtained by the above method, 1 to 500 mg of the extract thereof, or the red pigment cartamine itself obtained by the above method, and safflower yellow per adult day. It is preferable that the pigment itself be contained in an amount capable of ingesting 1 to 500 mg of a dye such as saphromin A.
- the health food of the present invention has, based on its total weight, a fraction containing the banana petal, the extract of the banana petal or the red pigment cartamine obtained therefrom! /, The red pigment cartamine itself or yellow.
- the fraction containing the pigment safflower yellow, or the yellow pigment safhumin A or the safflower yellow itself is used in an amount of 0.1 to 30% by weight, preferably 1 to 10% by weight, so long as it does not adversely affect the taste and appearance of the food. % By weight.
- the active ingredient in the antidiabetic agent in addition to the active ingredient in the antidiabetic agent, other known compounds commonly used in the pharmaceutical field, and compounds necessary for molding into a form suitable for oral administration, such as lactose, starch, and hydroxypropyl It may contain cellulose, kaolin, talc, calcium carbonate and the like.
- the powder and Z or the extract of the banana petal which is the pharmaceutical composition, may be used together with pharmaceutically acceptable salts, excipients, preservatives, coloring agents, flavoring agents, etc. in the field of pharmaceutical or food production. It can be used in various forms such as powders, solutions, granules, tablets, capsules and the like suitable for oral administration by known methods.
- the liquid preparation may be any of a solution and a suspension.
- Carriers include water, hydrogenated castor oil, glycerin, propylene glycol, ethanol, fatty oils, ethylene glycol, polyethylene glycol, and sorbitol.
- the precipitate was suspended in water and freeze-dried to obtain 2.6 g of a freeze-dried product (4).
- the lyophilized product (4) is a mixture containing the red pigment carthamin as a result of HPLC analysis. This freeze-dried product (4) is used for a postprandial blood glucose elevation inhibitory effect test using rats.
- the water-insoluble lyophilized product (3) and the water-insoluble lyophilized product (4) were each suspended in purified water, and administered as a lyophilized product by oral gavage at the dose shown in Table 1, and 15 minutes later.
- Glucose 2.5 g / kg was administered by oral gavage.
- Blood samples were collected from the jugular vein at 30, 60, and 120 minutes after glucose administration to measure blood glucose levels. It was measured with SYNCHRON CX3 ⁇ (BECKMAN).
- Table 1 shows that the extract group of the present invention exhibits an excellent postprandial blood glucose elevation inhibitory effect.
- Table 2 shows that the extract group of the present invention exhibits excellent postprandial blood glucose elevation inhibitory action.
- Rats were fasted for 18 hours, blood was collected from the jugular vein, and blood glucose was measured using SYNCHRON CX3 ⁇ .
- Blood glucose elevation suppression rate (%) ⁇ 1-[(Extract administration group blood glucose level-before administration of extract administration) Extract administration group blood glucose level) / (Control group blood glucose level-Control group blood glucose level before start of extract administration)] ⁇ ⁇
- Table 3 shows that the extract group of the present invention shows an excellent postprandial blood glucose elevation inhibitory effect.
- Example 11 Dissolve all of the above composition in 800 mL of distilled water, add distilled water to make the total volume 100 mL, sterilize with a 0.22 m sterilization filter, and aseptically fill 100 mL each brown bottle to prepare in Example 2. A drink was produced containing 100 mg of the above-mentioned active ingredient for antidiabetic agents of the present invention.
- Example 11 Dissolve all of the above composition in 800 mL of distilled water, add distilled water to make the total volume 100 mL, sterilize with a 0.22 m sterilization filter, and aseptically fill 100 mL each brown bottle to prepare in Example 2. A drink was produced containing 100 mg of the above-mentioned active ingredient for antidiabetic agents of the present invention.
- Example 11 Example 11
- sucrose fatty acid ester 1 part by weight of sucrose fatty acid ester
- the ingredients excluding the fragrance, heart-strength, thyme, and sucrose fatty acid ester are mixed well in a mill, and then distilled water is added and kneaded to an appropriate moldable viscosity.
- heart strength, thyme and sucrose fatty acid ester are added and further kneaded.
- a flavor is added, and granules are produced by extrusion granulation. After drying the granules at 40 ° C, they were molded using a tableting machine to produce chewable tablets.
- Example 1 A gelatin capsule was prepared by filling 50 mg of a water-insoluble freeze-dried product of a banana petal (Example 4) into a gelatin capsule skin (oval, weight 150 mg) composed of the above composition. 14
- sucrose esternole 5 parts by weight of sucrose esternole
- the above composition was mixed and stirred to prepare a uniform mixture, and tablets were produced using a tableting machine.
- Industrial applicability The banana petals and Z or the extract thereof of the present invention can be effectively used as a preventive or therapeutic agent for diabetes or a healthy food.
Abstract
Description
Claims
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2006511808A JP4516958B2 (ja) | 2004-03-31 | 2005-03-31 | 抗糖尿病用組成物 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004-105034 | 2004-03-31 | ||
JP2004105034A JP2007063130A (ja) | 2004-03-31 | 2004-03-31 | 抗糖尿病用組成物 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2005094858A1 true WO2005094858A1 (ja) | 2005-10-13 |
Family
ID=35063520
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2005/006319 WO2005094858A1 (ja) | 2004-03-31 | 2005-03-31 | 抗糖尿病用組成物 |
Country Status (2)
Country | Link |
---|---|
JP (2) | JP2007063130A (ja) |
WO (1) | WO2005094858A1 (ja) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007037425A1 (ja) * | 2005-09-29 | 2007-04-05 | Kureha Corporation | 抗糖尿病用組成物 |
JP2008231101A (ja) * | 2007-02-23 | 2008-10-02 | Kureha Corp | 抗糖尿病剤 |
CN102675379A (zh) * | 2011-03-15 | 2012-09-19 | 河北以岭医药研究院有限公司 | 一种从红花中提取精制羟基红花黄色素a的方法 |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104230864A (zh) * | 2013-06-08 | 2014-12-24 | 浙江永宁药业股份有限公司 | 新的羟基红花黄色素a二价药用盐及其制备方法和用途 |
CN103980239B (zh) * | 2013-02-07 | 2016-04-13 | 浙江永宁药业股份有限公司 | 羟基红花黄色素a钠及其生产方法和用途 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1250618A (zh) * | 1999-09-07 | 2000-04-19 | 朱长征 | 有益于糖尿病、冠心病及肿瘤患者的食品配料及制作方法 |
WO2001076614A1 (fr) * | 2000-04-10 | 2001-10-18 | Takara Bio Inc. | Remedes |
JP2001346555A (ja) * | 2000-06-07 | 2001-12-18 | Senju Shokuhin Kk | 植物抽出エキス飲料、およびその製造方法 |
JP2003040780A (ja) * | 2001-07-23 | 2003-02-13 | Toyo Ink Mfg Co Ltd | 高脂血症抑制剤、高コレステロール血症抑制剤もしくは抗肥満剤 |
JP2003125733A (ja) * | 2001-08-03 | 2003-05-07 | Toyo Ink Mfg Co Ltd | 高脂血症もしくは高コレステロール血症改善用補助食品および高血圧症もしくは肝機能障害を改善する補助食品を提供する。 |
-
2004
- 2004-03-31 JP JP2004105034A patent/JP2007063130A/ja active Pending
-
2005
- 2005-03-31 WO PCT/JP2005/006319 patent/WO2005094858A1/ja not_active Application Discontinuation
- 2005-03-31 JP JP2006511808A patent/JP4516958B2/ja not_active Expired - Fee Related
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1250618A (zh) * | 1999-09-07 | 2000-04-19 | 朱长征 | 有益于糖尿病、冠心病及肿瘤患者的食品配料及制作方法 |
WO2001076614A1 (fr) * | 2000-04-10 | 2001-10-18 | Takara Bio Inc. | Remedes |
JP2001346555A (ja) * | 2000-06-07 | 2001-12-18 | Senju Shokuhin Kk | 植物抽出エキス飲料、およびその製造方法 |
JP2003040780A (ja) * | 2001-07-23 | 2003-02-13 | Toyo Ink Mfg Co Ltd | 高脂血症抑制剤、高コレステロール血症抑制剤もしくは抗肥満剤 |
JP2003125733A (ja) * | 2001-08-03 | 2003-05-07 | Toyo Ink Mfg Co Ltd | 高脂血症もしくは高コレステロール血症改善用補助食品および高血圧症もしくは肝機能障害を改善する補助食品を提供する。 |
Non-Patent Citations (2)
Title |
---|
IGARASHI Y. ET AL: "Benibana Shikiso no Koshippei Shokuhin Sozai to Shite no Kino Kaihatsu", URAKAMI ZAIDAN KENKYU HOKOKUSHO, vol. 6, 1998, pages 88 - 100, XP002998114 * |
MATSUBA S. ET AL: "Benibana Seibun no Seitainai ni Okeru Kosanka Sayo", JOURNAL OF JAPANESE SOCIETY OF NUTRITION, vol. 56, no. 6, 2003, pages 365 - 369, XP002998115 * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007037425A1 (ja) * | 2005-09-29 | 2007-04-05 | Kureha Corporation | 抗糖尿病用組成物 |
JP2008231101A (ja) * | 2007-02-23 | 2008-10-02 | Kureha Corp | 抗糖尿病剤 |
CN102675379A (zh) * | 2011-03-15 | 2012-09-19 | 河北以岭医药研究院有限公司 | 一种从红花中提取精制羟基红花黄色素a的方法 |
CN102675379B (zh) * | 2011-03-15 | 2015-08-19 | 河北以岭医药研究院有限公司 | 一种从红花中提取精制羟基红花黄色素a的方法 |
Also Published As
Publication number | Publication date |
---|---|
JP4516958B2 (ja) | 2010-08-04 |
JP2007063130A (ja) | 2007-03-15 |
JPWO2005094858A1 (ja) | 2008-07-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101464337B1 (ko) | 고욤나무 추출물을 유효성분으로 함유하는 항비만용 조성물 | |
KR101419463B1 (ko) | 간질환 예방 및 치료용 생약 조성물 | |
JP7007663B2 (ja) | クロモジ抽出物 | |
JP4516958B2 (ja) | 抗糖尿病用組成物 | |
WO2005074961A1 (ja) | 体脂肪調整剤 | |
JPH07119176B2 (ja) | 抗活性酸素作用組成物並びにこれを有効成分とする抗活性酸素剤、食品、化粧料及び医薬品 | |
KR20130097537A (ko) | 강황, 석창포, 원지의 열수추출물의 혼합물을 유효성분으로 포함하는 인지력 및 기억력 향상용 조성물 | |
EP1583547B1 (en) | Anti-obesity ingredients from medicinal plants and their composition | |
JP2006160710A (ja) | 糖尿病の予防・治療用組成物およびその有効成分を含む健康食品 | |
KR101292931B1 (ko) | 백운풀 추출물을 유효성분으로 포함하는 비알콜성 지방간질환의 예방 또는 치료용 조성물 | |
KR101018403B1 (ko) | 콩잎 추출물을 유효성분으로 함유하는 통풍 예방,지연 또는 치료용 조성물 | |
JP2007070263A (ja) | 糖尿病予防用組成物 | |
KR20150072660A (ko) | 잔대 추출물을 포함하는 간 보호용 조성물 | |
KR102014922B1 (ko) | 감초 유래 글라블리딘을 유효성분으로 하는 소화기능 개선용 조성물 | |
KR20180079920A (ko) | 토사자 추출물을 유효성분으로 함유하는 간섬유화 또는 간경화 예방, 개선 또는 치료용 조성물 | |
KR101894491B1 (ko) | 지각 초임계 추출물을 유효성분으로 함유하는 기억력 또는 인지 기능 개선용 조성물 | |
KR101248378B1 (ko) | 관절염 치료 및 예방용 약학조성물 | |
JP3142192B2 (ja) | 血中脂質改善剤及びこれを含有する組成物 | |
KR100888068B1 (ko) | 비만 억제용 조성물 | |
KR20160059152A (ko) | 엉겅퀴 잎 추출물을 유효성분으로 함유하는 항비만 조성물 | |
KR20150072659A (ko) | 청미래 추출물을 포함하는 간 보호용 조성물 | |
KR20150031373A (ko) | 비타민나무 잎 추출물을 유효성분으로 함유하는 비만 예방 또는 치료용 약학 조성물 및 식품 조성물 | |
KR20200076185A (ko) | 엉겅퀴 및 양파를 포함하는 혼합물을 함유하는 간질환의 개선, 예방 또는 치료용 조성물 | |
KR101662887B1 (ko) | 다래순 추출물을 유효성분으로 포함하는 비알콜성 지방간의 예방 또는 치료용 조성물 | |
KR102302047B1 (ko) | 엉겅퀴, 민들레, 배, 아로니아 및 꿀로 이루어진 혼합물을 함유하는 간보호 또는 숙취해소용 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DPEN | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2006511808 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 05727996 Country of ref document: EP Kind code of ref document: A1 |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 5727996 Country of ref document: EP |